-       Report 
   - October 2025
    -  189 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - March 2025
    -  200 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                 -       Report 
   - March 2025
    -  175 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - January 2025
    -  175 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - January 2025
    -  175 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - November 2025
    -  383 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                  -       Report 
   - August 2025
    -  138 Pages 
    Global
   
   From       €2287EUR$2,549USD£2,008GBP 
      €2691EUR$2,999USD£2,362GBP 
                  -       Report 
   - March 2025
    -  150 Pages 
    Global
   
   From       €3455EUR$3,850USD£3,032GBP 
      €4352EUR$4,850USD£3,820GBP 
                  -       Report 
   - June 2025
    -  160 Pages 
    Global
   
   From       €3699EUR$4,123USD£3,247GBP 
      €4352EUR$4,850USD£3,820GBP 
                -       Report 
   - September 2023
    -  110 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                -       Report 
   - March 2024
    -  200 Pages 
    Global
   
   From       €3724EUR$4,150USD£3,268GBP 
                  -       Report 
   - April 2023
    -  200 Pages 
    United States
   
   From       €2692EUR$3,000USD£2,363GBP 
      €3365EUR$3,750USD£2,953GBP 
                  -       Report 
   - April 2023
    -  394 Pages 
    Global
   
   From       €5384EUR$6,000USD£4,725GBP 
      €6730EUR$7,500USD£5,907GBP 
                -       Report 
   - February 2024
    -  120 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                -       Report 
   - April 2023
    -  116 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                  -       Report 
   - May 2024
    -  134 Pages 
    Global
   
   From       €4957EUR$5,524USD£4,351GBP 
      €5832EUR$6,499USD£5,118GBP 
                  -       Report 
   - May 2024
    -  130 Pages 
    Global
   
   From       €4957EUR$5,524USD£4,351GBP 
      €5832EUR$6,499USD£5,118GBP 
             
         Carmustine is a chemotherapy drug used to treat lymphoma, a type of cancer that affects the lymphatic system. It is a nitrogen mustard alkylating agent, meaning it works by damaging the DNA of cancer cells, preventing them from growing and dividing. It is usually administered intravenously, and is often used in combination with other drugs. Common side effects include nausea, vomiting, hair loss, and fatigue.
Carmustine is a widely used drug in the treatment of lymphoma, and is available in both    generic and branded forms. It is typically prescribed by oncologists and hematologists, and is available in both oral and injectable forms. It is also used in combination with other drugs, such as rituximab, to treat more advanced forms of lymphoma.
The Carmustine market is highly competitive, with a number of companies offering branded and generic versions of the drug. Some of the major players in the market include Bristol-Myers Squibb, Pfizer, Merck, Novartis, and Teva Pharmaceuticals. Show Less   Read more